Beam Therapeutics (BEAM) Total Debt (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Total Debt data on file, last reported at $105.4 million in Q1 2026.

• Total Debt for Q1 2026 came in at $105.4 million, up 1926.79% year-over-year; the trailing twelve-month figure through Mar 2026 was $105.4 million (up 1926.79% YoY), and the FY2025 annual result was $7.7 million, down 8.33% from the prior year.
• Total Debt rose to $105.4 million in Q1 2026 per BEAM's latest filing, from $7.7 million in the prior quarter.
• Over five years, Total Debt peaked at $105.4 million in Q1 2026 and troughed at $3.9 million in Q2 2025.
• A 5-year average of $17.5 million and a median of $10.8 million in 2023 frame the typical range for Total Debt.
• The sharpest annual moves came in 2022 and 2026: Total Debt tumbled 80.8% in 2022, then jumped 1926.79% in 2026.
• A 5-year view of Total Debt shows it stood at $18.3 million in 2022, then plunged by 40.98% to $10.8 million in 2023, then retreated by 22.22% to $8.4 million in 2024, then declined by 8.33% to $7.7 million in 2025, then jumped by 1268.74% to $105.4 million in 2026.
• Business Quant data shows BEAM's Total Debt at $105.4 million in Q1 2026, $7.7 million in Q4 2025, and $6.5 million in Q3 2025.